Lin BioScience, Inc. (TPEX:6696)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
399.50
+18.00 (4.72%)
Jun 5, 2026, 1:55 PM CST
Market Cap33.09B +239.2%
Revenue (ttm)n/a
Net Income-1.36B
EPS-16.60
Shares Out 82.83M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume521,091
Open384.50
Previous Close381.50
Day's Range378.00 - 400.50
52-Week Range130.00 - 510.00
Beta0.23
Analystsn/a
Price Targetn/a
Earnings DateAug 13, 2026

About Lin BioScience

Lin BioScience, Inc., a drug development company, develops therapies for oncology, ophthalmology, and metabolic diseases. Its product pipeline includes LBS-008, an oral therapy for dry age-related macular degeneration (Dry AMD)and stargardt diseases (STGD1), which is under Phase 3 clinical trial to evaluate safety and efficacy in adolescent STGD1 and under phase 2 or phase 3 clinical trial to evaluate safety and efficacy in Dry AMD; LBS-007, a natural non-ATP CDC7 inhibitor for the treatment of cancers; LBS-002, an anti-tubulin to treat primary... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Zhengqi Wang
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 6696
Full Company Profile

Financial Performance

Financial Statements